Moderna agreed to pay $950 million up front and up to $1.3 billion more to settle lipid nanoparticle patent claims by Arbutus and Genevant.
Moderna has agreed to pay $950 million upfront and up to an additional $1.3 billion contingent on the outcome of Moderna's appeal.
Moderna agreed to pay $950 million up front and up to $1.3 billion more to settle lipid nanoparticle patent claims by Arbutus and Genevant.